



# UNIVERSITY OF SOUTH ALABAMA

## OFFICE OF RESEARCH COMPLIANCE AND ASSURANCE

### TABLE OF CONTENTS: IRB POLICIES AND PROCEDURES

<b>100</b>	<b>Human Subjects Protection Program</b>
101	Regulatory and Ethical Mandate
102	Mission and Authority
103	Activities Requiring Review
104	Conflicts of Interest: IRB Members and Staff
105	Conflicts of Interest: Investigators
106	Training and Education
107	Policy and Procedures Maintenance
108	Common Rule 2018 Implementation
<b>200</b>	<b>IRB Organization and Administration</b>
201	IRB Membership and Duties
202	Ancillary Committee Reviews
<b>300</b>	<b>IRB Functions and Operations</b>
301	Meeting Preparation
302	Materials for Review
303	Meeting Procedures and IRB Actions
<b>400</b>	<b>Records and Documentation</b>
401	IRB Meeting Agenda
402	IRB Meeting Minutes
403	IRB Record Keeping
<b>500</b>	<b>IRB Review</b>
501	IRB Review
502	Exempt Research
503	Exempt Research - Limited IRB Review
504	Expedited Research
505	Study Completion, Suspension or Termination
506	Criteria for IRB Approval of Research
507	Risks to Subjects

<b>600</b>	<b>Incident Reporting</b>
601	Unanticipated Problems and Adverse Event Reporting
602	Protocol Deviations, Violations and Exceptions
<b>700</b>	<b>Informed Consent and HIPAA</b>
701	Informed Consent
702	Consent Documentation
703	Informed Consent: Research Involving Children
704	HIPAA Authorization
705	Translation and Interpretation
706	Posting of Informed Consent for Clinical Trials
<b>800</b>	<b>Special Topics</b>
801	Research Involving Data and Biological Specimens
802	Research Involving Secondary Data
803	Social and Behavioral Research
804	Internet Research
805	Case Studies/Reports
806	Involvement in Clinical Research for Non-Health Care Providers
<b>900</b>	<b>Vulnerable Populations</b>
901	Research Involving Children
902	Research Involving Pregnant Women, Fetuses, and Neonates
903	Research Involving Prisoners
904	Decisionally Impaired Participants
905	Students and Employees
<b>1000</b>	<b>FDA-Regulated Research</b>
1001	Medical Devices: Significant Risk/Non-Significant Risk Determinations
1002	Emergency Use: Investigational Drugs, Biologics and Device
1003	Compassionate/Treatment Use
1004	Humanitarian Use Device
<b>1100</b>	<b>External IRB Review</b>
1101	Western IRB
1102	National Cancer Institute: Central IRB
1103	External Institutional Review Boards
<b>1200</b>	<b>Participant Protection</b>
1201	Advertising and Subject Recruitment Materials
1202	Recruitment of Research Participants
1203	Compensation/Incentives for Participation
1204	Data Safety Monitoring Plan
1205	Certificate of Confidentiality
<b>1300</b>	<b>Quality Assurance and Improvement</b>
1301	Quality Assurance Review Program